These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935 [TBL] [Abstract][Full Text] [Related]
24. Focal Therapy of Prostate Cancer Using Irreversible Electroporation. Valerio M; Ahmed HU; Emberton M Tech Vasc Interv Radiol; 2015 Sep; 18(3):147-52. PubMed ID: 26365544 [TBL] [Abstract][Full Text] [Related]
25. [Irreversible electroporation (IRE) : A minimally invasive therapeutic option in prostate cancer]. Wiggermann P; Brünn K; Bäumler W Radiologe; 2017 Aug; 57(8):637-640. PubMed ID: 28477079 [TBL] [Abstract][Full Text] [Related]
26. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922 [TBL] [Abstract][Full Text] [Related]
27. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844 [TBL] [Abstract][Full Text] [Related]
29. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial. Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911 [TBL] [Abstract][Full Text] [Related]
30. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Valerio M; Dickinson L; Ali A; Ramachandran N; Donaldson I; Freeman A; Ahmed HU; Emberton M Contemp Clin Trials; 2014 Sep; 39(1):57-65. PubMed ID: 25072507 [TBL] [Abstract][Full Text] [Related]
31. Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1-2b Study). Sood A; Jeong W; Palma-Zamora I; Abdollah F; Butaney M; Corsi N; Wurst H; Arora S; Kachroo N; Hassan O; Gupta N; Gorin MA; Menon M Eur Urol; 2022 Apr; 81(4):396-406. PubMed ID: 34872786 [TBL] [Abstract][Full Text] [Related]
32. A retrospective study of CT-guided percutaneous irreversible electroporation (IRE) ablation: clinical efficacy and safety. Wang Z; Lu J; Huang W; Wu Z; Gong J; Wang Q; Liu Q; Wang C; Zhu Y; Ding X; Wang Z BMC Cancer; 2021 Feb; 21(1):124. PubMed ID: 33546635 [TBL] [Abstract][Full Text] [Related]
33. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy]. Heidenreich A; Ohlmann C; Ozgür E; Engelmann U Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521 [TBL] [Abstract][Full Text] [Related]
34. Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial. Wang H; Xue W; Yan W; Yin L; Dong B; He B; Yu Y; Shi W; Zhou Z; Lin H; Zhou Y; Wang Y; Shi Z; Ren S; Gao X; Wang L; Xu C JAMA Surg; 2022 Aug; 157(8):693-700. PubMed ID: 35793110 [TBL] [Abstract][Full Text] [Related]
35. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study. Geboers B; Gondoputro W; Thompson JE; Reesink DJ; van Riel LAMJG; Zhang D; Blazevski A; Doan P; Agrawal S; Matthews J; Haynes AM; Liu Z; Delprado W; Shnier R; de Reijke TM; Lawrentschuk N; Stijns PEF; Yaxley JW; Scheltema MJ; Stricker PD Eur Urol Focus; 2022 Nov; 8(6):1591-1598. PubMed ID: 35577751 [TBL] [Abstract][Full Text] [Related]
36. Irreversible electroporation (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience. Wah TM; Lenton J; Smith J; Bassett P; Jagdev S; Ralph C; Vasudev N; Bhattarai S; Kimuli M; Cartledge J Eur Radiol; 2021 Oct; 31(10):7491-7499. PubMed ID: 33825033 [TBL] [Abstract][Full Text] [Related]
37. Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome. Giganti F; Stabile A; Giona S; Marenco J; Orczyk C; Moore CM; Allen C; Kirkham A; Emberton M; Punwani S Magn Reson Imaging; 2019 May; 58():143-147. PubMed ID: 30768957 [TBL] [Abstract][Full Text] [Related]
38. Personalized Treatment Strategy in "Low-Risk Prostate Cancer Active Surveillance Candidates" Using Irreversible Electroporation: Prospective Evaluation of Feasibility, Morbidity, Functional and Oncological Outcomes. Popeneciu IV; Mohr MN; Strauß A; Leitsmann C; Trojan L; Reichert M World J Mens Health; 2024 Oct; 42(4):821-829. PubMed ID: 38311374 [TBL] [Abstract][Full Text] [Related]
39. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation. Scheltema MJ; Chang JI; van den Bos W; Böhm M; Delprado W; Gielchinsky I; de Reijke TM; de la Rosette JJ; Siriwardana AR; Shnier R; Stricker PD Eur Urol Focus; 2019 Jul; 5(4):585-591. PubMed ID: 29102671 [TBL] [Abstract][Full Text] [Related]
40. Real-World Comparative Safety and Effectiveness of Irreversible Electroporation and High-Intensity Focused Ultrasound for Prostate Cancer Ablation. Cribbs KA; Manning EF; Zhou J; Lahue BJ; Polascik TJ Urology; 2023 Apr; 174():7-17. PubMed ID: 36736917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]